Streetbeat News

Analyst Ratings

FFIV

RBC Capital analyst Matthew Hedberg maintains a 'Sector Perform' rating on F5 (NASDAQ:FFIV) and lowers the price target from $173 to $160.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:24 pm

KO

JP Morgan analyst Andrea Teixeira maintains an Overweight rating on Coca-Cola (NYSE:KO) and raises the price target from $59 to $62.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:23 pm

DOW

RBC Capital analyst Arun Viswanathan maintains a 'Sector Perform' rating on Dow (NYSE:DOW) and has lowered the price target from $54 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:22 pm

ARCC

JP Morgan analyst Melissa Gorham maintains an Overweight rating on Ares Capital (NASDAQ:ARCC) and raises the price target from $20.5 to $21.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:22 pm

MMM

JP Morgan analyst Stephen Tusa maintains a Neutral rating on 3M (NYSE:MMM) and raises the price target from $104 to $105.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:21 pm

DOV

RBC Capital analyst Deane Dray has maintained a 'Sector Perform' rating on Dover (NYSE:DOV) and lowered the price target from $149 to $145.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:20 pm

BIIB

Biogen Inc. has reported new Phase 1b clinical data from the study of BIIB080, a therapy targeting tau in mild Alzheimer's disease. The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living. The results were presented at the 2023 Clinical Trials on Alzheimer's Disease meeting. Biogen is currently recruiting for the Phase 2 CELIA study, evaluating the potential for this therapy to slow the worsening of mild cognitive impairment or mild dementia due to Alzheimer's disease. BIIB shares are trading lower by 2.26% to $246.41.

Portfolio Pulse from Nabaparna Bhattacharya

October 25, 2023 | 4:20 pm

RUN

Sunrun's stock is trading lower following negative commentary from Muddy Waters Research.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:19 pm

DHR

RBC Capital analyst Conor McNamara has maintained an 'Outperform' rating on Danaher (NYSE:DHR), but lowered the price target from $246 to $239.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:17 pm

USNA

DA Davidson analyst Linda Bolton Weiser has maintained a Neutral rating on Usana Health Sciences (NYSE:USNA) and lowered the price target from $62 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 4:17 pm